AstraZeneca cleared to market Fasenra biologic for asthma
WILMINGTON, Del. — AstraZeneca plans to release Fasenra, its newly approved biologic drug for severe asthma, to U.S. pharmacies in the coming weeks. Fasenra (benralizumab), approved this week by the Food and Drug Administration, is indicated for the add-on maintenance treatment of patients ages 12 and older with severe asthma and an eosinophilic phenotype. AstraZeneca said
